Sertraline and Lyrica (Pregabalin) Interaction
Sertraline and pregabalin can be safely used together without significant pharmacokinetic drug interactions, though patients should be monitored for additive central nervous system effects such as sedation and dizziness.
Pharmacokinetic Safety Profile
The combination is fundamentally safe from a drug interaction standpoint. Pregabalin undergoes negligible metabolism (<2% metabolized), is predominantly excreted unchanged in urine, and does not bind to plasma proteins, making pharmacokinetic interactions with other medications—including sertraline—highly unlikely 1. The FDA labeling explicitly states that pregabalin is unlikely to be involved in significant pharmacokinetic drug interactions 1.
Clinical Considerations
Additive CNS Effects
While no pharmacokinetic interactions occur, pregabalin can produce additive effects on cognitive and gross motor functioning when combined with other CNS-active medications 1. When prescribing this combination, counsel patients about:
- Increased sedation or somnolence (common with both medications individually)
- Dizziness (particularly prominent with pregabalin)
- Impaired coordination or cognitive slowing
Patients should avoid driving or operating heavy machinery until they understand how the combination affects them.
Practical Clinical Use
This combination has been studied and used successfully in clinical practice:
- In epilepsy patients with comorbid depression/anxiety, the combination of sertraline 100mg daily plus pregabalin 300mg daily (added to baseline antiepileptic drugs) demonstrated high efficacy and safety over 6 months 2
- Both medications are considered first-line agents for their respective primary indications—sertraline for depression/anxiety 3 and pregabalin for neuropathic pain and generalized anxiety disorder 4
Monitoring Parameters
When using this combination:
- Start with standard dosing for each medication
- Monitor for excessive sedation, particularly during titration
- Watch for dizziness-related falls, especially in elderly patients
- Assess functional impairment at follow-up visits
- No specific laboratory monitoring is required for the interaction itself
Common Pitfalls to Avoid
Do not avoid this combination due to unfounded interaction concerns—the evidence clearly supports its safety. The main clinical challenge is managing overlapping side effects (sedation, dizziness), not dangerous drug interactions. If CNS side effects become problematic, consider dose reduction of one or both agents rather than discontinuing effective therapy.
Pregabalin requires renal dose adjustment 4, so verify kidney function before prescribing, particularly in elderly patients or those on multiple medications.